細胞免疫 の ナノスケール コントローラー と し て エクソソーム を 再プログラム する
Qinqin Cheng1, Xiaojing Shi1, Menglu Han1
1Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy , University of Southern California , Los Angeles , California 90089 , United States.
Journal of the American Chemical Society
|November 20, 2018
まとめ
研究者は 癌細胞を標的とする エクソソームを設計し 免疫系T細胞を効率的に殺すようにしました この新しいナノ医療アプローチである 合成マルチバレント抗体 リターゲットエクソソーム (SMART-Exos) は 細胞のないがん免疫療法に 期待を寄せています
科学分野:
- ナノ医療
- 免疫学
- 腫瘍学
背景:
- エクソソームは 治療的な可能性を持つ天然の膀です
- 現在のナノ医学は 治療薬の効率的な投与に依存しています
- 細胞免疫,特に細胞毒性T細胞は 癌を殺すのに不可欠です.
研究 の 目的:
- 細胞免疫のコントローラーとして内生的に派生したエクソソームを探求する.
- 細胞毒性T細胞を癌細胞に 誘導し活性化する
- 遺伝子組み換えエクソソームを用いた 新種のがん免疫療法を開発する
主な方法:
- 遺伝的に2つの異なる抗体を エクソソームの表面に表示しています
- 合成された多価抗体 (SMART-Exos) を生成する.
- T細胞CD3およびがん細胞関連表皮成長因子受容体 (EGFR) を標的とする抗体を利用する.
主要な成果:
- SMART-ExosはT細胞とEGFRを発現するがん細胞の相互リンクを誘導した.
- 強力な抗腫瘍免疫を in vitro と in vivo で実証した.
- 癌の免疫療法に エンジニアリングされたエクソソームの使用の概念を検証した.
結論:
- エンジニアリングされたエクソソームは 細胞の免疫を人工的に制御します
- SMART-Exosは 癌の免疫療法に 新たな多角的なアプローチを 提供しています
- この研究は 細胞なしの癌治療の 新種への道を開くのです
関連する概念動画
Combinatorial Gene Control
9.7K
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
9.7K
What is the Immune System?
128.0K
Overview
128.0K
Overview of Exosomes
3.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.7K
Humoral Immune Responses
83.9K
Overview
83.9K
Introduction to Nuclear Reprogramming
2.3K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
2.3K
Methods of Nuclear Reprogramming
2.1K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.1K


